Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07072234
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Clear Cell Carcinoma
  • Growth Factor
  • Phase 1

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Lymphodepleting chemotherapy — DRUG
    Given by IV
  • Dexamethasone — DRUG
    Given PO
  • Fludarabine — DRUG
    Given by IV
  • Cyclophosphamate — DRUG
    Given by IV
  • TGFBR-2 KO CD70 CAR NK — DRUG
    Given by IV

Study Details

Testing an investigational cancer therapy called TGFBR-2 KO CD70 CAR NK cell therapy.

Key Dates

Start date
Sep 25, 2025
Status verified
Apr 2026
Primary completion
Feb 1, 2028
Completion
Feb 1, 2030

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Dose-optimization phase
  • Experimental: Dose-expansion phase

Primary Outcome Measure

Safety and adverse events (AEs) [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
Andrew C Johns, MD
[email protected]
713-745-0138
Andrew C Johns, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
MD Anderson Cancer Center· Houston, TX

Related Studies